Announcements Trials
Browse Landscape

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 9INDUSTRY 5OTHER_GOV 1FED 1

Study Type

Observational 5Interventional 4

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 467Neoplasms 315Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 207Lung Neoplasms 176Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 59Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

daratumumab 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Patient Preference × Clear all
NCT06125795 2026-05-01

PROVIDENCE

AbbVie

Active not recruiting
146 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Patient Preference

NCT05284591 2024-10-01

MYLENE

iOMEDICO AG

Completed
96 enrolled
Plasma cell

Multiple Myeloma, Personal Satisfaction, Patient Satisfaction, Patient Preference

NCT05115006 2022-06-30

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Bristol-Myers Squibb

Completed
294 enrolled
Dermatologic

Melanoma, Patient Preference

NCT02616692 2017-09-27

HCC Patient Preferences in Japan

Bayer

Completed
120 enrolled
Gastrointestinal

Liver Neoplasms, Patient Preference

NCT00721981 2010-12-10

An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy

AstraZeneca

Terminated
120 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡